RNA binding motif protein Y-linked family 2 member K, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RBMY2KP profile across patient tissues and cancer cell-line models. RBMY2KP expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RBMY2KP is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, RBMY2KP RNA expression shows 4,335 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, LUSC, and STAD as cancer lineages where RBMY2KP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMY2KP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMY2KP survival associations across molecular data types. RBMY2KP RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMY2KP RNA expression–survival associations across cancer types. High RBMY2KP expression shows unfavorable associations in DLBC, KIRP, SKCM, ESCA, READ and PCPG. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for RBMY2KP RNA expression.
This table summarizes RBMY2KP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMY2KP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMY2KP shows higher tumor expression in LUSC. The LUSC box plot shows higher RBMY2KP RNA expression in tumor versus normal tissue (log2 FC = +0.049, t-test p = .047).
This table shows molecular features associated with RBMY2KP in patient tissues and cancer cell lines. In patient samples, RBMY2KP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
